Figure 2.
The comparison of progression‐free survival in the first‐line of treatment (PFS1) between patients that received a pertuzumab‐based regimen (Pert) and those who did not (No Pert) in the overall population (a), in triple‐positive patients (b), in Er‐ or PgR‐positive patients (c) and in HRs‐negative patients (d). Abbreviations: Er, estrogen receptor; PgR, progesterone receptor; HRs, hormone receptors.